Core Viewpoint - Apyx Medical Corporation will release its financial results for Q2 of fiscal year 2025 on August 7, 2025, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 4:30 p.m. Eastern Time on the same day [2] - Interested parties can join the call by dialing 800-717-1738 or 646-307-1865 for international callers, using access code 35370 [2] - A live webcast of the call will be available on the company's website and will be archived for future reference [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products like Renuvion and the AYON Body Contouring System™ [3] - The company’s Helium Plasma Platform Technology is utilized in both cosmetic surgery and hospital surgical markets, providing surgeons with controlled heat to achieve desired results [3] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical publications, showcasing the company's commitment to clinical validation [3] - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Core Insights - Apyx Medical Corporation reported a total revenue of $9.4 million for Q1 2025, a decrease from $10.2 million in the same period last year, primarily due to a significant drop in OEM revenue [5][7] - The Advanced Energy segment saw a 6% increase in revenue to $7.9 million, driven by strong sales of generator units and single-use handpieces [4][5] - The company is preparing to launch the AYON Body Contouring System in the second half of 2025, pending FDA clearance, which is expected to enhance its market position in surgical aesthetics [3][5] Financial Performance - Total revenue decreased by 8% year-over-year, with Advanced Energy revenue increasing by 6% while OEM revenue fell by 45% [5][7] - Gross profit for Q1 2025 was $5.7 million, with a gross profit margin of 60%, up from 58% in the prior year [8] - Operating expenses decreased significantly by $3.8 million to $8.7 million, reflecting cost-cutting measures implemented in the previous quarter [9] Loss and Adjusted EBITDA - The net loss attributable to stockholders decreased by 45% to $4.2 million, or $0.10 per share, compared to a loss of $7.6 million, or $0.22 per share, in Q1 2024 [11][20] - Adjusted EBITDA loss improved to $2.4 million from $5.3 million in the prior year, indicating better operational efficiency [11][26] Market Position and Strategy - Renuvion, the company's flagship product, was awarded the 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener," highlighting its growing recognition in the market [5][11] - The company aims to capitalize on the increasing demand for aesthetic procedures, particularly among patients using GLP-1 drugs for weight loss [3][5] - Apyx Medical's management expressed confidence in the company's path to profitability following recent restructuring and cost management efforts [6][9]

Company Overview - Apyx Medical Corporation is an advanced energy technology company focused on innovative products, including its Helium Plasma Platform Technology marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market [3] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical publications, demonstrating the company's commitment to clinical validation [3] Financial Results Announcement - Apyx Medical will release its financial results for the first quarter of fiscal year 2025 before markets open on Thursday, May 8th [1] - A conference call will be held at 8:00 a.m. Eastern Time on the same day to discuss the quarterly results and include a question-and-answer session [2] Investor Relations - The investor relations contact for Apyx Medical is Jeremy Feffer, Managing Director at LifeSci Advisors, who can be reached at 212-915-2568 or via email [3]